Date: 2011-02-22
Type of information: Fundraising
Company: VitamFero (France)
Investors: CapDecisif Management (France) G1J Ile-de-France (France)
Amount: €1.1 million
Funding type: seed capital
Planned used: These fundings will allow VitamFero to develop its products (novel vaccines first against Apicomplexe parasites such as Toxoplasma gondii (toxoplasmosis agent), Neospora caninum (neosporosis agent) and Plasmodium (malaria agent)) and to strenghten its patent portfolio until its next financing round in 2013.
Others:
Therapeutic area: Infectious diseases
